Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9

Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL) will host a conference call on November 9, 2022, at 8:00 a.m. ET to discuss its third-quarter financial results for the period ending September 30, 2022. Investors can dial in at (800) 715-9871 or (646) 307-1963 and will need the conference ID 6188743 to join. The call will also be accessible via a live audio webcast on the company's investor relations website. Avadel focuses on innovative drug delivery solutions, notably its lead candidate LUMRYZ, intended for treating narcolepsy.

Positive

• Scheduled conference call for Q3 financial results, indicating ongoing transparency and investor engagement.
• Lead candidate LUMRYZ addresses significant medical needs in narcolepsy treatment.

Negative

• None.

DUBLIN, Ireland, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a.m. ET on Wednesday, November 9, 2022, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2022.

To access the live conference call, investors are invited to dial (800) 715-9871 or (646) 307-1963 (International). When joining the call, please ask to join the Avadel Pharmaceuticals call or state the conference ID 6188743. A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.

About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, LUMRYZ, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of EDS and cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687

Media Contact:
Gabriella Greig
Real Chemistry
ggreig@realchemistry.com
(203) 249-2688

FAQ

When is Avadel Pharmaceuticals' Q3 earnings call?

Avadel Pharmaceuticals' Q3 earnings call is scheduled for November 9, 2022, at 8:00 a.m. ET.

How can I access the Avadel Pharmaceuticals conference call?

You can access the Avadel Pharmaceuticals conference call by dialing (800) 715-9871 or (646) 307-1963, using conference ID 6188743.

What is LUMRYZ developed by Avadel Pharmaceuticals?

LUMRYZ is an investigational formulation of sodium oxybate designed for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy.

Where can I find the live audio webcast of Avadel's conference call?

The live audio webcast of Avadel's conference call can be found in the investor relations section of their website.

What financial results will Avadel discuss in their upcoming call?

Avadel will discuss its financial results for the third quarter ending September 30, 2022, during the conference call.